Protecting the Microbiota-Reference-Cited by-同舟云学术

Protecting the Microbiota

Published:2021-04-10 Issue:Supplement_3 Volume:223 Page:S290-S295
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Rooney C M¹²^ORCID,Ahmed S¹²,Wilcox M H¹²^ORCID

Affiliation:

1. Leeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom

2. Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, United Kingdom

Abstract

Abstract We examine 3 different approaches to protecting the gut microbiome: highly targeted antibiotics, antibiotic destruction, and antibiotic binding. Each approach shows promise to prevent the off-target effects of antibiotics on the gut microbiome.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiab143/37017851/jiab143.pdf

Reference41 articles.

1. Colonization Resistance of the Gut Microbiota against Clostridium difficile. Antibiotics (Basel);Pérez-Cobas,2015

2. The human gut microbiome—a potential controller of wellness and disease. Frontiers in Microbiology;Kho,2018

3. Narrow-spectrum antibacterial agents;Melander;Medchemcomm,2018

4. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections;Vickers;BMC Infect Dis,2015

5. Ridinilazole: a novel therapy for Clostridium difficile infection;Vickers;Int J Antimicrobial Agents,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Public health case for microbiome-sparing antibiotics and new opportunities for drug development;mSphere;2024-08-28

2. Identification of ethyl-6-bromo-2((phenylthio)methyl)imidazo[1,2-a]pyridine-3-carboxylate as a narrow spectrum inhibitor of Streptococcus pneumoniae and its FtsZ;European Journal of Medicinal Chemistry;2024-03

3. Oral cholestyramine prevents enrichment of diverse daptomycin-resistance mutations in intestinal Enterococcus faecium;2022-05-25

4. An orally administered drug prevents selection for antibiotic-resistant bacteria in the gut during daptomycin therapy;Evolution, Medicine, and Public Health;2022-01-01

5. The State of Microbiome Science at the Intersection of Infectious Diseases and Antimicrobial Resistance;The Journal of Infectious Diseases;2021-03-01